You might also like
Hologic, Inc. is a medical technology company dedicated to advancing women's health through early detection and treatment solutions. The company operates in four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, offering a range of products that contribute significantly to its revenue . Hologic's offerings include advanced diagnostic assays, breast cancer care solutions, gynecological surgical products, and bone health assessment tools . In fiscal year 2023, the company reported total revenue of $4.03 billion, with each division achieving double-digit organic growth, excluding the impact of COVID-19 .
- Diagnostics - Offers a wide range of diagnostic products, including molecular diagnostic assays on systems like Panther and Panther Fusion, detecting infectious microorganisms, high-risk HPV strains, and other viruses. Includes the ThinPrep cytology system for cervical cancer screening and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment .
- Breast Health - Provides solutions for breast cancer care, including 3D digital mammography systems, image analysis software, and minimally invasive breast biopsy systems, with strong revenue growth driven by increased gantry shipments and robust service revenue .
- GYN Surgical - Includes products like the MyoSure hysteroscopic tissue removal system and the NovaSure endometrial ablation system, with significant growth driven by MyoSure and Fluent systems .
- Skeletal Health - Offers products for bone health assessment, being the smallest contributor to overall revenue compared to the other segments .
-
With the slowing of Panther placements after the pandemic , how do you plan to sustain growth in molecular diagnostics revenue, and can you provide more details on strategies to drive assay adoption without new instrument placements?
-
Given the upcoming launch of the new gantry in Breast Health and the potential impact on revenue in fiscal '25 , how are you addressing the risk of customers delaying purchases, and what steps are you taking to ensure revenue stability in this segment?
-
Regarding your recent acquisition of Gynasonix , can you elaborate on how the Sonata system complements your existing GYN Surgical portfolio without cannibalizing products like MyoSure, and what specific synergies do you expect to achieve?
-
With the reported transitory headwinds such as supply chain shortages and IV fluid issues , can you quantify the expected financial impact on fiscal '25, and what strategies are you implementing to mitigate these challenges?
-
In terms of capital allocation, given your recent M&A activities and share repurchase programs , how are you balancing investments in organic growth versus returning capital to shareholders, and what should investors expect in terms of future capital deployment?
Competitors mentioned in the company's latest 10K filing.
- Roche Diagnostics: Primary competitor in the Diagnostics business .
- Becton Dickinson: Primary competitor in the Diagnostics business .
- Siemens Healthineers: Primary competitor in the Breast & Skeletal Health business .
- GE Healthcare: Primary competitor in the Breast & Skeletal Health business .
- Johnson & Johnson: Primary competitor in the GYN Surgical business .
- Medtronic: Primary competitor in the GYN Surgical business .
- F. Hoffmann-LaRoche Ltd: Parent company of Roche, a supplier and competitor in the Diagnostics business .
- GE Healthcare Bio-Sciences Corp.: Supplies membranes for ThinPrep product line and is a competitor in the Breast Health and Skeletal Health businesses .
Recent developments and announcements about HOLX.
Financial Reporting
-
Total Revenue: $1,021.8 million, representing a 0.9% increase compared to the prior year period. On a constant currency basis, revenue grew by 1.0%, aligning with the company's guidance.
-
Divisional Performance:
- Diagnostics: Revenue of $470.6 million, up 5.1% (5.2% on a constant currency basis).
- Breast Health: Revenue of $369.1 million, down 2.3% (-2.1% on a constant currency basis).
- GYN Surgical: Revenue of $166.3 million, up 2.5%.
- Skeletal Health: Revenue of $15.8 million, down 37.8% (-37.4% on a constant currency basis).
-
Earnings Per Share (EPS): Both GAAP and non-GAAP EPS are expected to be near the high end of the guidance ranges provided in November 2024.
-
Currency Impact: The strengthening of the U.S. dollar reduced revenue by approximately $9 million compared to earlier guidance.
-
Upcoming Full Results: Hologic plans to release its finalized Q1 fiscal 2025 results on February 5, 2025, along with updated financial guidance for Q2 and the full fiscal year.
Earnings Report
Hologic, Inc. (HOLX) Preliminary Earnings Results for Q1 Fiscal 2025
Hologic, Inc. has announced its preliminary revenue results for the first quarter of fiscal 2025, which ended on December 28, 2024. Below are the key highlights:
These results reflect Hologic's resilience despite currency headwinds and a challenging macroeconomic environment. The company will also present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, where further insights may be shared.
Corporate Leadership
- Sally W. Crawford: Retiring from the Board after 17 years of service. Her decision is unrelated to any disagreements with management or the Board.
- Scott T. Garrett: Reaching the retirement age as per the company's Corporate Governance Guidelines and will not be re-nominated.
- Sally W. Crawford is retiring voluntarily after long service.
- Scott T. Garrett is stepping down due to reaching the mandatory retirement age.
- The Board size will be reduced to eight directors following these departures.
Leadership Change
Who is leaving:
Why:
Who is stepping up:
Board Change
Martin Madaus has been appointed to the Board of Directors of Hologic, Inc., effective December 6, 2024. He will also serve on the Compensation Committee and the Nominating and Corporate Governance Committee .